• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Senti Biosciences, Inc. - Common Stock (NQ: SNTI )

    2.440 +0.190 (+8.44%)
    Streaming Delayed Price Updated: 1:27 PM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Senti Biosciences, Inc. - Common Stock

    < Previous 1 2 Next >
    Senti Bio Announces Reverse Stock Split
    Shares expected to begin trading on split-adjusted basis on July 18, 2024 
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
    Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices. 
    Via MarketBeat
    Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
    $8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia 
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio to Participate in Upcoming Conferences
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio to Participate in Upcoming Investor Conferences
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
    Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages 
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio to Participate in Upcoming Investor Conferences
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Senti Biosciences Announces New Employment Inducement Grants
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio to Present at the SVB Securities Global Biopharma Conference
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.